AI in Prior Authorization: Where the Efficiency Gains Are and Where the Risk Lives

Prior authorization is one of the most frequently cited AI use cases in healthcare, and for good reason. It is high volume, heavily rules-based in parts, and a well-documented source of administrative burden for providers and delay for patients. It is also one of the most compliance-sensitive processes a payer or health system runs, because a prior authorization decision is, functionally, a coverage decision that directly affects patient care. Getting the automation boundary right in this use case is not a technical footnote. It is the entire project.

Where AI Genuinely Accelerates the Process

The strongest, least controversial gains are on the front end of the workflow. AI is well suited to intake and completeness review: checking whether a request includes the required clinical documentation, flagging missing fields, and routing requests to the correct queue based on procedure type or urgency. It is also effective at applying well-established, unambiguous clinical criteria to straightforward, low-risk requests, allowing clean approvals to move through in a fraction of the time a manual review would take. And it has real value in aggregating and summarizing clinical documentation for the human reviewers who handle more complex cases, reducing the time a nurse or medical director spends hunting through a chart before they can apply their judgment. In each of these cases, AI is accelerating work that leads up to a decision, or handling decisions where the criteria are narrow and well defined.

Where the Risk Lives

The risk concentrates precisely where the request stops being a clean pattern match. Denials are the clearest example. A denial is a decision with direct clinical and financial consequences for a patient, it is subject to appeal, and increasingly it is subject to regulatory scrutiny over whether the process that generated it was fair and clinically sound. Several states have already passed legislation requiring that adverse determinations involve a qualified clinical reviewer, not an algorithm acting alone, and federal scrutiny of AI-driven denials has intensified. Requests involving ambiguous or conflicting clinical documentation, rare or complex conditions, and cases at the edge of a coverage policy's stated criteria all require the kind of contextual judgment that current AI systems should not be making unsupervised. The failure mode is not always a dramatic, obviously wrong denial. It is often a subtly inappropriate one, applied at scale, that only becomes visible after a pattern of harm or complaint emerges.

Where the Line Should Sit

• Automate intake, completeness checks, and routing, administrative work with no clinical judgment component.
• Accelerate clean approvals against narrow, well-defined, low-risk criteria, with audit sampling to confirm the criteria are being applied correctly.
• Support, but do not replace, complex reviews by summarizing documentation and surfacing relevant criteria for the human reviewer.
• Keep denials, appeals, and edge-of-policy cases with a qualified clinical reviewer, full stop, regardless of how confident the model's recommendation appears.

The Governance Layer That Makes This Defensible

None of this works without documentation that shows the line was deliberately drawn and is being actively enforced, not just described in a policy document. That means an auditable record of which decisions were AI-assisted versus AI-adjudicated, monitoring of denial rates and overturn rates by category to catch drift, and a clear escalation path when a case falls outside the criteria the system was validated against. Organizations that get prior authorization automation right are not the ones that automate the most. They are the ones that can prove, case by case, exactly where the algorithm's role ended and a clinician's judgment began. That is the difference between an efficiency initiative and a liability.